WO1999012968A3 - Chemokine peptides, variants, derivatives and analogs, their use in methods to inhibit or augment an inflammatory response - Google Patents

Chemokine peptides, variants, derivatives and analogs, their use in methods to inhibit or augment an inflammatory response Download PDF

Info

Publication number
WO1999012968A3
WO1999012968A3 PCT/US1998/019052 US9819052W WO9912968A3 WO 1999012968 A3 WO1999012968 A3 WO 1999012968A3 US 9819052 W US9819052 W US 9819052W WO 9912968 A3 WO9912968 A3 WO 9912968A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
derivatives
analogs
augment
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/019052
Other languages
French (fr)
Other versions
WO1999012968A2 (en
Inventor
David J Grainger
Lauren Marie Tatalick
Suzanne T Kanaly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Priority to JP2000510773A priority Critical patent/JP4523151B2/en
Priority to EP98946057A priority patent/EP1012187B1/en
Priority to AU93153/98A priority patent/AU9315398A/en
Priority to DE69841105T priority patent/DE69841105D1/en
Priority to CA002303422A priority patent/CA2303422A1/en
Priority to AT98946057T priority patent/ATE440863T1/en
Publication of WO1999012968A2 publication Critical patent/WO1999012968A2/en
Publication of WO1999012968A3 publication Critical patent/WO1999012968A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.
PCT/US1998/019052 1997-09-11 1998-09-11 Chemokine peptides, variants, derivatives and analogs, their use in methods to inhibit or augment an inflammatory response Ceased WO1999012968A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000510773A JP4523151B2 (en) 1997-09-11 1998-09-11 Chemokine peptides, variants, derivatives and analogs thereof and their use in methods of inhibiting or increasing inflammatory responses
EP98946057A EP1012187B1 (en) 1997-09-11 1998-09-11 Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
AU93153/98A AU9315398A (en) 1997-09-11 1998-09-11 Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
DE69841105T DE69841105D1 (en) 1997-09-11 1998-09-11 CHEMOKINES PEPTIDES, VARIANTS, DERIVATIVES AND ANALOGS. YOUR USE IN METHOD FOR INHIBITING OR INCREASING A REFLECTION OF LIGHT
CA002303422A CA2303422A1 (en) 1997-09-11 1998-09-11 Chemokine peptides, variants, derivatives and analogs, their use in methods to inhibit or augment an inflammatory response
AT98946057T ATE440863T1 (en) 1997-09-11 1998-09-11 CHEMOKINE PEPTIDES, VARIANTS, DERIVATIVES AND ANALOGUES. THEIR USE IN METHOD FOR INHIBITING OR INCREASE AN INFLAMMATORY RESPONSE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/927,939 US6989435B2 (en) 1997-09-11 1997-09-11 Compounds and methods to inhibit or augment an inflammatory response
US08/927,939 1997-09-11

Publications (2)

Publication Number Publication Date
WO1999012968A2 WO1999012968A2 (en) 1999-03-18
WO1999012968A3 true WO1999012968A3 (en) 1999-07-29

Family

ID=25455479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/019052 Ceased WO1999012968A2 (en) 1997-09-11 1998-09-11 Chemokine peptides, variants, derivatives and analogs, their use in methods to inhibit or augment an inflammatory response

Country Status (9)

Country Link
US (2) US6989435B2 (en)
EP (1) EP1012187B1 (en)
JP (1) JP4523151B2 (en)
AT (1) ATE440863T1 (en)
AU (1) AU9315398A (en)
CA (1) CA2303422A1 (en)
DE (1) DE69841105D1 (en)
ES (1) ES2332616T3 (en)
WO (1) WO1999012968A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US8853200B2 (en) 2007-08-02 2014-10-07 Cambridge Enterprise Limited Treatment of rheumatoid arthritis with 3-amino lactam compounds

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
CA2363067C (en) * 1999-01-12 2012-03-20 David J. Grainger Compounds and methods to inhibit or augment an inflammatory response
US7208152B2 (en) 1999-11-24 2007-04-24 Millennium Pharmaceuticals, Inc. Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof
EP1176200A3 (en) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases or wound healing and their use in indentifying pharmacologically acitve substances
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
MXPA04002575A (en) * 2001-09-20 2004-06-18 Schering Corp Chemokines as adjuvants of immune response.
DK1482973T3 (en) * 2002-03-15 2009-12-07 Schering Corp Method for modulating CD200 receptors
CA2547651C (en) 2003-12-01 2015-06-23 Cambridge University Technical Services Limited Anti-inflammatory agents
WO2005060968A1 (en) * 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US8137397B2 (en) * 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
GB2418426A (en) 2004-08-18 2006-03-29 Univ Cambridge Tech Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
WO2006074179A2 (en) * 2005-01-04 2006-07-13 University Of Rochester Blockade of elr+cxc chemokines as a treatment for inflammatory and autoimmune disease
US20060247760A1 (en) * 2005-04-29 2006-11-02 Medtronic Vascular, Inc. Methods and apparatus for treatment of aneurysms adjacent branch arteries
WO2006126188A2 (en) * 2005-05-25 2006-11-30 Hadasit Medical Research Services And Development Ltd. Cxcr4 antagonists for wound healing and re-epithelialization
GB0512238D0 (en) 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
US7713521B2 (en) 2005-08-12 2010-05-11 Schering Corporation MCP1 fusions
EP2025762A3 (en) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex tracking assay
US7405195B2 (en) * 2006-03-27 2008-07-29 Natural Beauty Bio-Technology Limited Cosmetic compositions
CA2694454A1 (en) * 2007-07-26 2009-02-05 Ipsen Pharma S.A.S. Chemokine analogs
US7662967B2 (en) 2007-08-02 2010-02-16 Cambridge Enterprise Limited Anti-inflammatory compounds and compositions
ES2342810B1 (en) 2008-09-10 2011-07-05 Pere Poch Marti ABREBOCAS PERFECTED FOR THE INTRODUCTION OF LINGING MASKS AND OTHER MEDICAL DEVICES THROUGH THE ORAL CAVITY.
EP3744729B1 (en) 2009-01-16 2023-03-01 Sederma Peptides, compositions comprising them and cosmetic and dermopharmaceutical uses
FR2941231B1 (en) 2009-01-16 2016-04-01 Sederma Sa NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES
FR2941232B1 (en) * 2009-01-16 2014-08-08 Sederma Sa NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES
KR20120022984A (en) * 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Immunonanotherapeutics providing a th1-biased response
WO2010138192A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
CN102905728B (en) 2010-05-26 2015-11-25 西莱克塔生物科技公司 Nanocarrier compositions with uncoupled adjuvants
GB201009603D0 (en) 2010-06-08 2010-07-21 Cambridge Entpr Ltd Anti-inflammatory agent
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
US20140045211A1 (en) * 2011-03-24 2014-02-13 The Regents Of The University Of California High level production of recombinant proteins
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
US9962428B2 (en) 2012-12-21 2018-05-08 National University Corporation Nagoya University Composition having tissue-repairing activity, and use therefor
ITRM20130199A1 (en) 2013-04-03 2014-10-04 Irbm Science Park S P A PEPTIDES FOR DERMATOLOGICAL AND / OR COSMETIC USE
CN109983121A (en) 2016-06-30 2019-07-05 昂克诺斯公司 The pseudotyping oncolytic virus of therapeutical peptide delivers
EP3731850A4 (en) * 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
US20240139376A1 (en) * 2021-02-12 2024-05-02 Rhode Island Hospital Reconstitution of extracellular matrixes for musculoskeletal joint tissue repair using biomimetic biologic and synthetic factors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004334A1 (en) * 1985-01-18 1986-07-31 MERCK Patent Gesellschaft mit beschränkter Haftung Immunoregulatory peptides
US5079228A (en) * 1990-02-05 1992-01-07 Board Of Regents, The University Of Texas System Peptide inhibitors of neutrophil activating factor induced chemotaxis
WO1992004372A1 (en) * 1990-09-12 1992-03-19 The Scripps Research Institute Active site of interleukin-8: polypeptide analogs and antibodies
WO1994020512A2 (en) * 1993-03-01 1994-09-15 Glycan Pharmaceuticals, Inc. Analogs for specific oligosaccharide-protein interactions and uses therefor
JPH0767689A (en) * 1993-05-31 1995-03-14 Chemo Sero Therapeut Res Inst Anti-LD78 polypeptide monoclonal antibody
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
WO1998012324A1 (en) * 1996-09-18 1998-03-26 Center For Blood Research, Inc. Monocyte chemotactic protein 5 (mcp-5) molecules and uses therefor

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2740788A (en) * 1956-04-03 J-hydroxy-n-propargyl-morphinanes
US2726243A (en) * 1954-01-08 1955-12-06 Ciba Pharm Prod Inc Hydrazides of yohimbic acid
US2743270A (en) * 1954-05-26 1956-04-24 Univ Michigan Heterocyclic nitrogen compounds
FR2135087B1 (en) 1971-05-06 1974-08-23 Serdex
FR2229403B2 (en) 1973-05-18 1976-08-13 Serdex Etud Rech Diffusion Ex
FR2239471A1 (en) 1973-08-03 1975-02-28 Omnium Chimique Sa Corynanthine hydrazides - as therapeutic agents
HU172479B (en) 1976-03-09 1978-09-28 Gyogyszerkutato Intezet Process for preparing compounds of ergolene and ergoline structure
US5248666A (en) 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
US4737580A (en) 1985-03-15 1988-04-12 Oncogen Platelet related growth regulator
JPS62501502A (en) * 1985-01-18 1987-06-18 イミユーンテツク・フアーマシユーテイカルズ immunomodulatory peptides
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4774318A (en) 1985-11-22 1988-09-27 Oncogen Snake venom growth arresting peptide
AU623589B2 (en) 1987-03-02 1992-05-21 Bristol-Myers Squibb Company Platelet related growth regulator
US5827821A (en) 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
US5202118A (en) 1987-12-18 1993-04-13 Immunex Corporation Method for promoting wound healing using IL-1
ATE131071T1 (en) 1988-08-15 1995-12-15 Brigham & Womens Hospital LEUKOCYTE ADHESION INHIBITOR.
IL92938A (en) 1989-01-01 1998-08-16 Us Commerce Polypeptide having human monocyte chemotactic factor
US5212073A (en) 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5179078A (en) 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
US5484885A (en) 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
IL95500A (en) 1989-09-11 1997-03-18 Matrix Pharma ANTI-PROLIFERATIVE COMPOSITIONS CONTAINING TGF-b PROTEIN IN A VISCOUS MATRIX AND THEIR USE
EP0502897A4 (en) 1989-11-29 1993-03-03 Brigham And Women's Hospital Endothelial-derived il-8
US5661132A (en) 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5155038A (en) 1990-02-22 1992-10-13 W. R. Grace & Co.-Conn. Use of thrombospondin to promote wound healing
US5190918A (en) 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
US5190920A (en) 1990-09-24 1993-03-02 W. R. Grace & Co.-Conn. Method for using synthetic analogs of thrombospondin for inhibiting metastasis activity
CA2041271A1 (en) 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5824647A (en) 1990-12-12 1998-10-20 Postlethwaite; Arnold E. Chemotactic wound healing peptides
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
JPH06510987A (en) 1991-06-21 1994-12-08 テンプル　ユニバーシティ　−　オブ　ザ　コモンウェルス　システム　オブ　ハイヤー　エデュケーション Calpain inhibitory peptide homolog of kininogen heavy chain
US5401651A (en) 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
US5707814A (en) 1991-11-01 1998-01-13 The Regents Of The University Of California CD8+ cell antiviral factor
US5326752A (en) 1991-11-27 1994-07-05 Glycomed Incorporated Substituted lactose and lactosamine derivatives as cell adhesion inhibitors
AU3078892A (en) 1991-12-04 1993-06-28 Biomedical Research Centre Limited, The Human interleukin-8 analogs
US5357041A (en) 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
JPH0625288A (en) 1992-07-10 1994-02-01 Kuraray Co Ltd Peptide or its salt
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5605671A (en) 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
WO1994009128A1 (en) 1992-10-22 1994-04-28 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5589458A (en) 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
US5627265A (en) 1993-03-05 1997-05-06 Washington University Receptor for cell-binding domain of thrombospondins
US5474983A (en) 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
AU697624B2 (en) 1993-08-13 1998-10-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for stimulating and inhibiting TGF-beta activity
JPH0782169A (en) 1993-09-13 1995-03-28 Toray Ind Inc Wound healing agent
US5510264A (en) 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
IL107268A0 (en) * 1993-10-12 1994-01-25 Yeda Res & Dev Molecules influencing the shedding of the tnf receptor, their preparation and their use
US5578714A (en) 1993-10-21 1996-11-26 New York Blood Center, Inc. DNA encoding Duffy 9pd protein
US5739103A (en) 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
US5459128A (en) 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
AU1397895A (en) 1993-12-22 1995-07-10 Temple University - Of The Commonwealth System Of Higher Education Peptide analogs of the activated platelet binding site on factor xi
AU1398595A (en) 1993-12-22 1995-07-10 Temple University - Of The Commonwealth System Of Higher Education Peptide analogs of the factor ixa platelet binding site
JP3532570B2 (en) 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Mammalian monocyte chemoattractant protein receptor
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
GB9406492D0 (en) 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
GB9406463D0 (en) 1994-03-31 1994-05-25 Medical Res Council Cervical ripening
US5627156A (en) 1994-09-23 1997-05-06 University Of Nebraska Board Of Regents Polypeptide agonists for human interleukin-8
US5877276A (en) 1994-09-23 1999-03-02 The Board Of Regents Of The University Of Nebraska Polypeptide agonists for human interleukin-8
US5684032A (en) 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
WO1996020722A1 (en) 1995-01-03 1996-07-11 Thomas Jefferson University Compounds that inhibit t cell proliferation and methods using the same
US5645837A (en) 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same
US6806061B1 (en) 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
EP0809492A4 (en) 1995-02-17 2007-01-24 Smithkline Beecham Corp Il-8 receptor antagonists
EP0814806A1 (en) 1995-02-23 1998-01-07 Janssen Pharmaceutica N.V. Use of fused benzothiazoles as neuroprotectants
WO1996029074A1 (en) 1995-03-22 1996-09-26 Eli Lilly And Company Methods of treating or preventing pain or nociception
US5817911A (en) 1995-04-07 1998-10-06 Regents Of The University Of California Transgenic mice expressing alveolar MCP-1
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
JPH11510792A (en) 1995-06-29 1999-09-21 トーマス ジェファーソン ユニバーシティー CD4-derived peptides that inhibit the immune response
GB9518611D0 (en) 1995-09-12 1995-11-15 Ludwig Inst Cancer Res Anti-apoptotic factors
ES2233978T3 (en) 1995-09-27 2005-06-16 SHIONOGI & CO., LTD. PROTEIN ANALOG TO CHEMIOCINE TYPE CC.
NZ320889A (en) 1995-09-29 2000-09-29 Immunex Corp A p35 protein which binds to and inhibits chemokines
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1997019173A1 (en) 1995-11-21 1997-05-29 Smithkline Beecham Corporation Method of treating sepsis
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
AU1532697A (en) 1996-01-12 1997-08-01 Genetics Institute Inc. Beta-chemokine, h1305 (mcp-2)
WO1997029192A1 (en) 1996-02-12 1997-08-14 Schering Corporation Mammalian dendritic cell chemokine reagents
AU5355996A (en) 1996-02-23 1997-09-10 Human Genome Sciences, Inc. Human chemokine polypeptides
EP0883687B1 (en) 1996-03-01 2004-10-27 Euroscreen S.A. C-c ckr-5, cc-chemikines receptor, derivatives thereof and their uses
JPH09255570A (en) 1996-03-21 1997-09-30 Fujitsuko Kk Drug and edible composition for reducing blood lipid level
WO1997035572A1 (en) 1996-03-28 1997-10-02 Smithkline Beecham Corporation Carboxylic acid indole inhibitors of chemokines
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
GB2319252A (en) 1996-11-08 1998-05-20 Diapharm Limited Polypeptides involved in the interaction of HIV gp120 with the fusin, and the CC-CKR-5 co-receptors thereof
US5700821A (en) 1996-07-30 1997-12-23 University Of Pittsburgh Phosphatase inhibitors and methods of use thereof
US6162455A (en) * 1997-01-22 2000-12-19 American Cyanamid Company Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals
JP3614610B2 (en) 1997-05-02 2005-01-26 新日鉄ソリューションズ株式会社 Mail transmission system, mail transmission method and recording medium
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
EP0906954A1 (en) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
US6265220B1 (en) 1998-06-29 2001-07-24 Edwin F. Ullman Assay for homocysteine
US7238711B1 (en) * 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO2001014886A2 (en) * 1999-08-23 2001-03-01 Polaris Pharmaceuticals, Inc. Inhibitors of binding between proteins and macromolecular ligands
CA2625196C (en) 2005-10-07 2016-04-05 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004334A1 (en) * 1985-01-18 1986-07-31 MERCK Patent Gesellschaft mit beschränkter Haftung Immunoregulatory peptides
US5079228A (en) * 1990-02-05 1992-01-07 Board Of Regents, The University Of Texas System Peptide inhibitors of neutrophil activating factor induced chemotaxis
WO1992004372A1 (en) * 1990-09-12 1992-03-19 The Scripps Research Institute Active site of interleukin-8: polypeptide analogs and antibodies
WO1994020512A2 (en) * 1993-03-01 1994-09-15 Glycan Pharmaceuticals, Inc. Analogs for specific oligosaccharide-protein interactions and uses therefor
JPH0767689A (en) * 1993-05-31 1995-03-14 Chemo Sero Therapeut Res Inst Anti-LD78 polypeptide monoclonal antibody
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
WO1998012324A1 (en) * 1996-09-18 1998-03-26 Center For Blood Research, Inc. Monocyte chemotactic protein 5 (mcp-5) molecules and uses therefor

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CHEM.PHARM.BULL., vol. 22, no. 11, 1974, pages 2680 - 2684 *
CHEMICAL ABSTRACTS, vol. 103, no. 17, 28 October 1985, Columbus, Ohio, US; abstract no. 137328, PORSCHKE E.A: "The configuration of single stranded oligonucleotides..." XP002095219 *
CHEMICAL ABSTRACTS, vol. 82, no. 11, 17 March 1975, Columbus, Ohio, US; abstract no. 73463, NAGAMATSU E.A.: "Hydrolysis of lysine peptides by plasmin" XP002095217 *
CHEMICAL ABSTRACTS, vol. 82, no. 13, 31 March 1975, Columbus, Ohio, US; abstract no. 84651, NOGUCHI: "Isolation and identification of acidic oligopeptides..." XP002095218 *
DATABASE WPI Section Ch Week 9519, Derwent World Patents Index; Class B04, AN 95-143871, XP002095220 *
GONG J H ET AL: "An antagonist of monocyte chemoattractant protein 1 ( MCP -1) inhibits arthritis in the MRL-lpr mouse model.", JOURNAL OF EXPERIMENTAL MEDICINE, (1997 JUL 7) 186 (1) 131-7. JOURNAL CODE: I2V. ISSN: 0022-1007., UNITED STATES, XP002095216 *
GONG J H ET AL: "Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues.", JOURNAL OF EXPERIMENTAL MEDICINE, (1995 FEB 1) 181 (2) 631-40. JOURNAL CODE: I2V. ISSN: 0022-1007., UNITED STATES, XP000605169 *
J.ARIC.FOOD CHEM., vol. 23, no. 1, - 1975, pages 49 - 53 *
J.BIOL.STRUCT.DYN., vol. 2, no. 6, 1985, pages 1173 - 1184 *
SIMMONS E.A.: "Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist", SCIENCE, vol. 276, 11 April 1997 (1997-04-11), pages 276 - 279, XP002095215 *
THOMPSON E.A.: "Design and evaluation of small peptides mapping the exposed surface of IL-8", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, vol. 47, 1996, COPENHAGEN DK, pages 214 - 218, XP002095213 *
WELLS E.A.: "The molecular basis of the chemokine/chemokine receptor interaction-scope for design of chemokine antagonists.", METHODS: A COMPANION TO METHODS OF ENZYMOLOGY, vol. 10, 1996, pages 126 - 134, XP002095214 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US8853200B2 (en) 2007-08-02 2014-10-07 Cambridge Enterprise Limited Treatment of rheumatoid arthritis with 3-amino lactam compounds

Also Published As

Publication number Publication date
US20010006640A1 (en) 2001-07-05
JP4523151B2 (en) 2010-08-11
DE69841105D1 (en) 2009-10-08
JP2001515918A (en) 2001-09-25
CA2303422A1 (en) 1999-03-18
AU9315398A (en) 1999-03-29
US7700087B2 (en) 2010-04-20
WO1999012968A2 (en) 1999-03-18
US20060073114A1 (en) 2006-04-06
ATE440863T1 (en) 2009-09-15
US6989435B2 (en) 2006-01-24
EP1012187B1 (en) 2009-08-26
ES2332616T3 (en) 2010-02-09
EP1012187A2 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
WO2000042071A3 (en) Compounds and methods to inhibit or augment an inflammatory response
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
AU4808597A (en) System to detect small molecule/peptide interaction
AU5551098A (en) Antiviral peptide derivatives
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
AU2002232736A1 (en) Electrically responsive promoter system
ZA975533B (en) Cyclosporin-containing pharmaceutical composition.
ZA975943B (en) Aqueous formulations of peptides.
AU2168597A (en) Improvements in or relating to encapsulation
AU2972097A (en) Peptide derivatives
AU1803597A (en) Peptide derivatives
AU2001247334A1 (en) Novel peptides with anti-hypertensive activity
NZ230654A (en) Anti-cell proliferative penta and hexa peptides
AUPO026596A0 (en) Viral peptide
AU1620099A (en) Ubiquitin-like conjugating protein
EP0372503A3 (en) Anticoagulant peptides
AU4401997A (en) Mannosylated peptides
ZA978948B (en) Novel therapeutically active adenosine derivatives.
AU2973100A (en) Novel agouti and agouti-related peptide analogs
WO2001011937A3 (en) Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines
AU2002217863A1 (en) Homing peptide multimers, their preparation and uses
WO1993003148A3 (en) Tau/neurofilament protein kinases pk40 and pk36
ZA9710254B (en) LH-RH peptide analogues, their uses and pharmaceutical composition containing them.
AU9118891A (en) Conformationally constrained peptides i
HUP0000490A3 (en) Cyclic peptide derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2303422

Country of ref document: CA

Ref country code: CA

Ref document number: 2303422

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 510773

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998946057

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998946057

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642